West Pharma Q1 sales jump 21%, operating profit surges 65% as securities lawsuit filed

Filed April 23, 2026 · Period ending March 31, 2026 · Compared to 10-Q Apr 24, 2025 · ~1 min read

Key Changes

• high

  Securities class action filed May 2025 alleges misleading statements about business prospects and improper insider stock sales between Feb 2023-Feb 2025; company filed motion to dismiss but cannot estimate potential losses.

  Legal Proceedings verify on EDGAR →
• high

  Q1 2026 net sales rose 21% to $844.9M (15.3% organic) driven by high-value components (Westar, NovaPure, FluroTec) and self-injection devices, reversing prior-year's 0.4% growth; operating profit jumped 65.5% to $177.1M.

  MD&A: Financial Results verify on EDGAR →
• high

  Gross margin expanded 1.9 points to 35.1% on favorable product mix and pricing power; operating margin reached 21.0% versus 15.3% prior year as restructuring charges fell to $1.4M from $17.8M.

  MD&A: Profitability verify on EDGAR →